Sermorelin is GRF(1-29) — the active core of GHRH, produced synthetically. It earned FDA approval in 1997 (Geref), the first synthetic GH secretagogue to clear the bar; EMD Serono pulled it in 2008 for manufacturing economics, not safety. That history gives it the most defensible legal position of any GH secretagogue in compounding today. But adult evidence is thin: the entire clinical case rests on Khorram et al. (1997) — 19 elderly subjects, 16 weeks, single-blind — showing +1.26 kg lean mass in men (not women), no significant fat loss, no bone-density change. Compared with tesamorelin's 816-patient Phase III program, the gap is not subtle. Where it earns its place: clean selectivity, preserved somatostatin feedback, and a gentler GH stimulus suited to recovery support during caloric restriction.

What Is Sermorelin?

The first 29 amino acids of GHRH (GRF 1-29) — the minimum fragment to fully activate the GHRH receptor and trigger GH release. ~3,358 Da, structurally unmodified, with a short IV half-life of 10–20 min; it clears within ~4 h though GH effects persist ~3 h after activation. The brevity is a feature — a crisp GH pulse mimicking what the pituitary does during deep sleep.

How Sermorelin Works

It activates the GHRH receptor on pituitary somatotrophs via the cAMP/PKA cascade — the same one endogenous GHRH uses. Like ringing the doorbell the hypothalamus rings each night during deep sleep.

The somatostatin brake (safety advantage): when GH/IGF-1 rise, the hypothalamus releases somatostatin telling the pituitary to stop — so sermorelin can't easily drive supraphysiological GH levels. Exogenous rhGH bypasses this feedback entirely, which is why rhGH risks supraphysiological GH while sermorelin makes overdose difficult. It preserves the natural pulsatile pattern. Clean selectivity: at physiological doses it doesn't elevate cortisol, ACTH, or prolactin — distinguishing it from older ghrelin-receptor agonists (GHRP-2, GHRP-6).

The FDA Story

1997 approval: Geref, for diagnosis/treatment of idiopathic GH deficiency in children, based on trials showing significant height-velocity increases over 12 months (data to 36 months). Less potent than rhGH at equivalent doses, but offering physiological regulation. 2008 commercial withdrawal: EMD Serono pulled it for manufacturing economics against entrenched rhGH products — not a safety action; prior approval was never revoked. Why it matters: under Section 503A, previously-FDA-approved compounds have the clearest compounding pathway. Sermorelin checks that box unambiguously, unlike CJC-1295 no-DAC (no human trials, no FDA history) or ipamorelin (Phase II for a different indication, never approved) — both briefly on the FDA Category 2 list in 2024.

Clinical Evidence

Pediatric: adequate for approval — significant height-velocity increases over 12 months (to 36 months), consistently less effective than rhGH at equivalent doses (the trade-off is physiological regulation vs raw potency). Adult: essentially one trial — Khorram et al. (1997), 19 subjects (ages 55–71), 16 weeks, single-blind. Improved: nocturnal GH, IGF-1, IGFBP-3, and lean mass in men only (~1.26 kg). No change: total body fat, BMI, bone density, or lean mass in women. Limitations: tiny sample, single-blind, gender-discordant, short duration, no functional endpoints. This single trial is the source of virtually every "sermorelin builds lean mass" claim; whether it generalizes to today's typical 35–55-year-old users is unknown.

Benefits: Evidence vs Marketing

Supported by direct evidence: reliable GH and IGF-1 elevation; limited lean-mass gain (Khorram, men only). Mechanism but not direct trial data: sleep quality (GH is tied to slow-wave sleep; MK-677 raised Stage 4 sleep ~50%, but sermorelin's sleep outcomes aren't directly measured), recovery/tissue repair. Claimed but unsupported: independent fat loss (Khorram found no change in body fat/BMI), and broad "anti-aging" — the GH-secretagogue class repeatedly raises lean mass without improving strength or function (MK-677, anamorelin).

Side Effects

Mild and well-characterized from its years as an approved product: transient facial flushing and injection-site reactions are most common; mild peripheral edema and tingling are less frequent than with tesamorelin. No cortisol/ACTH/prolactin elevation at standard doses. The somatostatin feedback provides an extra safety margin. Periodic IGF-1 testing is prudent during extended use.

Sermorelin vs Tesamorelin

Both are GHRH-receptor agonists. Structure: sermorelin is GRF(1-29), unmodified; tesamorelin keeps the full 44-aa sequence plus a trans-3-hexenoic acid group protecting against DPP-IV, giving modestly better stability. Evidence: tesamorelin has two Phase III RCTs (N=816, CT-measured visceral fat) vs sermorelin's one 19-subject adult trial. Regulatory: tesamorelin is currently FDA-approved (Egrifta) for HIV-associated lipodystrophy; sermorelin was approved but commercially withdrawn — both legally compoundable. Why choose sermorelin: better tolerability in edema-sensitive people, lower cost via compounding, and a gentler stimulus when maximal potency isn't the goal.

Legal Status and Compounding

Sermorelin's position is the clearest of any GH secretagogue in compounding: its 1997 FDA approval and non-safety withdrawal fit the 503A pathway cleanly, unlike CJC-1295 no-DAC and ipamorelin (regulatory uncertainty; PCAC declined to recommend ipamorelin for the 503A Bulks List in October 2024). FDA enforcement against compounded peptides tightened in late 2024 (warning letters, 40+ state AGs), primarily targeting GLP-1s but with broader implications; sermorelin's prior approval offers some insulation. Available by prescription through compounding pharmacies; a research compound otherwise; WADA-prohibited for competitive athletes.